Business Wire

Enevate Unveils New HD-Energy® Technology Details at the 33rd International Battery Seminar

Del

Dr. Benjamin Park, Enevate Corporation’s Founder and Chief Technology Officer, discussed technical details behind the company’s HD-Energy Technology at this week’s 33rd International Battery Seminar in Ft. Lauderdale, Florida. Dr. Park disclosed the technology and benefits of Enevate’s new silicon-dominant Li-ion battery innovations overcoming the obstacles of other and more traditional silicon approaches. Unlike graphite-dominant anodes that only include a small percentage of silicon-containing additive, Enevate is manufacturing silicon-dominant anodes as a proprietary active material film with over 70 percent silicon content.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160323005018/en/

Edge of Enevate’s silicon-dominant anode magnified at 100X. Enevate’s self-standing monolithic anode ...

Edge of Enevate’s silicon-dominant anode magnified at 100X. Enevate’s self-standing monolithic anode enables Li-ion batteries with both ultrafast charging and high energy density. (Photo: Business Wire)

“It’s exciting to see what started off as an anode technology mainly targeting high energy density show additional benefits such as ultrafast charging. The unique properties of our developed silicon-dominant conductive active material film has led to additional benefits for mobile users,” said Dr. Park. “For example, we have demonstrated ultrafast charging with 90 percent cell charge in 15 minutes and 50 percent in as little as 5 minutes, and benchmarks are showing between 35 percent to 50 percent longer smartphone runtime.”

Enevate’s innovations, supported by 25 issued and pending patents, allow for a silicon composite anode with a gravimetric energy density of about 2800 mAh/g and very high initial Coulombic efficiencies of 93 percent for the anode and 90 percent for full cells, while controlling the well-known issues associated with volumetric expansion and contraction. The composite is comprised of carbon as a conductive matrix, silicon as the main active material, and silicon-carbide as a nanometer-scale layer protecting the silicon surface. In addition, Enevate technology is compatible with current high-volume manufacturing processes, leading to lower costs and providing the ability for use in existing form-factors.

Dr. John Goodenough, a key inventor of the modern Li-ion battery, said, “Enevate is using a different technical approach for silicon anodes that is truly unique and innovative to deliver both ultrafast charging and high energy density. I‘m impressed that their technology and process is practical, highly manufacturable, and has the potential to be sufficiently inexpensive for high-volume mobile devices.”

About  Enevate  ( www.enevate.com )

Enevate Corporation is an advanced rechargeable energy storage company focused on next-generation mobile devices and drones with global headquarters in Irvine, CA. Enevate’s batteries with its breakthrough HD-Energy Technology delivers significant performance improvement over conventional Li-ion batteries. Investors include Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, and CEC Capital. Enevate, the Enevate logo, and HD-Energy are registered trademarks and eBoost is a trademark of the Enevate Corporation.

Contact information

Enevate Corporation
Amanda Smith, +1-480-568-7993
asmith@enevate.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia12.12.2017 00:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 chimeric antigen receptor T (CAR T) cell therapy, which is investigational for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). With a minimum of eight weeks of follow-up, 71 percent of ALL patients (n=17/24) who received a single infusion of KTE-C19 achieved complete tumor remission (complete remission (CR) or CR with incomplete hematological recovery). The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005311/en/ ALL is an aggressive type of blood cancer which can also involve the lymph nodes, spleen, liver, central

NTT Communications Strengthens its DDoS Protection Services with New Detection Solution11.12.2017 23:00Pressemelding

NTT Communications Corporation (NTT Com), the global data and IP services arm of Fortune Global 500 telecom leader NTT (TYO: 9432), announced that it is expanding its Distributed Denial of Service Protection Services (DPS) with the addition of DPS Detect. This new solution can help customers detect potential attacks directed to their networks and initiate mitigations faster. DDoS attacks can strike at any time, potentially crippling network infrastructure and severely degrading the performance and reachability of a website or other IP-accessible assets. The expanded DPS suite of services will enable Global IP Network customers around the world to easily customize the level of service and assistance that best fits their needs. “Network security is one of the top priorities for our company,” said Michael Wheeler, executive vice president of the NTT Communications

Interactive Brokers Launches Bitcoin Futures Trading at the Start of Trading December 10th, 201711.12.2017 16:28Pressemelding

Interactive Brokers Group, Inc. (NASDAQ GS:IBKR), a global electronic brokerage firm, began offering clients the ability to trade bitcoin futures at the start of trading on the Cboe Futures Exchange (CFE) on Sunday night, December 10th, 2017. In addition to offering bitcoin futures from the CFE, under the ticker symbol GXBT, the company plans to offer bitcoin futures from the Chicago Mercantile Exchange (CME) at the scheduled start of trading December 18th using the symbol BRR. IBKR was there at the start of trading and its systems operated normally. “Interactive Brokers was on the buy side of the low print of 14,710,” said Thomas Peterffy, founder, Chairman and CEO of Interactive Brokers. “A Registered Investment Advisor on the Interactive Brokers platform purchased two March contracts in the first minute of trading.” As of 9:15am ET on Monday, the company said that

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 201711.12.2017 13:00Pressemelding

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim’s two-pronged research strategy – investigating both cancer cell-directed therapies and immune cell-directed therapies. This multi-faceted approach offers the potential to bring innovative opportunities to the Boehringer Ingelheim oncology portfolio and novel therapies to patients. “Immuno-oncology is radically shifting the research and treatment landscape in oncology. We believe that the greatest success in difficult-to-treat cancers will be achieved with immuno-oncology and its combination with cancer cell directed therapy, which is why we are committing significant resources in both areas,” said Jonathon Sedgwick, Ph.D., Vice

Valence Advises SK Capital on Its Acquisition of ICL’s Fire Safety and Oil Additives Businesses11.12.2017 12:47Pressemelding

The Valence Group acted as lead financial advisor to SK Capital Partners on its announced acquisition of the Fire Safety and Oil Additives businesses of Israel Chemicals Ltd. (“ICL”) for approximately $1 billion. The transaction is expected to close during the first half of 2018. The Businesses, headquartered in St. Louis, Missouri, have global operations and are market leaders in each of their segments. The ICL Fire Safety business is a formulator and manufacturer of fire management chemicals. Its Phos-Chek fire retardants, Class A and B foams, and water enhancing gels are the world’s leading chemical solutions for managing wildland, military, industrial and municipal fires, and are used in partnership with fire management agencies across the globe. The ICL Oil Additives business provides high quality phosphorus pentasulfide used in the preparation of ZDDP-based lubricant additives, i

Smith & Nephew Announce European Launch of Handheld Imaging Technology Heralding a New Era of Evidence-Based Decision Making in Wound Care11.12.2017 10:18Pressemelding

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the European launch of MolecuLight i:X TM, the easy to use, handheld imaging device that instantly measures wound surface area and visualises the presence and distribution of potentially harmful bacteria in wounds.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005434/en/ Currently wound assessments are made with the naked eye which can lack the accuracy required to most effectively guide clinical decision making.4 Using fluorescence, MolecuLight i:X quickly, safely, and easily visualises potentially harmful bacteria1,2,3 in wounds which may otherwise lack signs or symptoms of infection. It enhances a clinician’s ability to choose the right therapy, at the right time for their patient1,

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom